197 related articles for article (PubMed ID: 35117190)
1. Research progress of cancer stem cells and IL-6/STAT3 signaling pathway in esophageal adenocarcinoma.
Chen M; Ye X; Wang R; Poon K
Transl Cancer Res; 2020 Jan; 9(1):363-371. PubMed ID: 35117190
[TBL] [Abstract][Full Text] [Related]
2. Esophageal Adenocarcinoma and Its Rare Association with Barrett's Esophagus in Henan, China.
Liu S; Dai JY; Yao L; Li X; Reid B; Self S; Ma J; Chang Y; Feng S; Tapsoba Jde D; Sun X; Sun X
PLoS One; 2014; 9(10):e110348. PubMed ID: 25333822
[TBL] [Abstract][Full Text] [Related]
3. Esophageal Cancer: Genomic and Molecular Characterization, Stem Cell Compartment and Clonal Evolution.
Testa U; Castelli G; Pelosi E
Medicines (Basel); 2017 Sep; 4(3):. PubMed ID: 28930282
[TBL] [Abstract][Full Text] [Related]
4. Gene Expression in Barrett's Esophagus Cell Lines Resemble Esophageal Squamous Cell Carcinoma Instead of Esophageal Adenocarcinoma.
Panda A; Bhanot G; Ganesan S; Bajpai M
Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885081
[TBL] [Abstract][Full Text] [Related]
5. Lipid droplet biogenesis and COX-2 pathway activation are triggered by Barrett's esophagus and adenocarcinoma, but not esophageal squamous cell carcinoma risk factors.
Carrossini N; Meireles Da Costa N; Andrade-Barreto E; Sousa VPL; Nicolau-Neto P; Souza-Santos PT; Mansur GR; Wernersbach L; Bozza PT; Viola JPB; Ribeiro Pinto LF
Sci Rep; 2021 Jan; 11(1):981. PubMed ID: 33441691
[TBL] [Abstract][Full Text] [Related]
6. siRNA Library Screening Identifies a Druggable Immune-Signature Driving Esophageal Adenocarcinoma Cell Growth.
Duggan SP; Garry C; Behan FM; Phipps S; Kudo H; Kirca M; Zaheer A; McGarrigle S; Reynolds JV; Goldin R; Kalloger SE; Schaeffer DF; Long A; Strid J; Kelleher D
Cell Mol Gastroenterol Hepatol; 2018; 5(4):569-590. PubMed ID: 29930979
[TBL] [Abstract][Full Text] [Related]
7. LgR5 expression and cancer stem cell hypothesis: clue to define the true origin of esophageal adenocarcinomas with and without Barrett's esophagus?
von Rahden BH; Kircher S; Lazariotou M; Reiber C; Stuermer L; Otto C; Germer CT; Grimm M
J Exp Clin Cancer Res; 2011 Feb; 30(1):23. PubMed ID: 21345220
[TBL] [Abstract][Full Text] [Related]
8. Bile acid exposure up-regulates tuberous sclerosis complex 1/mammalian target of rapamycin pathway in Barrett's-associated esophageal adenocarcinoma.
Yen CJ; Izzo JG; Lee DF; Guha S; Wei Y; Wu TT; Chen CT; Kuo HP; Hsu JM; Sun HL; Chou CK; Buttar NS; Wang KK; Huang P; Ajani J; Hung MC
Cancer Res; 2008 Apr; 68(8):2632-40. PubMed ID: 18413730
[TBL] [Abstract][Full Text] [Related]
9. Drug-induced expression of EpCAM contributes to therapy resistance in esophageal adenocarcinoma.
Sun X; Martin RCG; Zheng Q; Farmer R; Pandit H; Li X; Jacob K; Suo J; Li Y
Cell Oncol (Dordr); 2018 Dec; 41(6):651-662. PubMed ID: 30116994
[TBL] [Abstract][Full Text] [Related]
10. Laryngopharyngeal reflux symptoms better predict the presence of esophageal adenocarcinoma than typical gastroesophageal reflux symptoms.
Reavis KM; Morris CD; Gopal DV; Hunter JG; Jobe BA
Ann Surg; 2004 Jun; 239(6):849-56; discussion 856-8. PubMed ID: 15166964
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic biomarkers in esophageal cancer.
Kaz AM; Grady WM
Cancer Lett; 2014 Jan; 342(2):193-9. PubMed ID: 22406828
[TBL] [Abstract][Full Text] [Related]
12. Expression profiles of cancer stem cell markers: CD133, CD44, Musashi-1 and EpCAM in the cardiac mucosa-Barrett's esophagus-early esophageal adenocarcinoma-advanced esophageal adenocarcinoma sequence.
Mokrowiecka A; Veits L; Falkeis C; Musial J; Kordek R; Lochowski M; Kozak J; Wierzchniewska-Lawska A; Vieth M; Malecka-Panas E
Pathol Res Pract; 2017 Mar; 213(3):205-209. PubMed ID: 28216140
[TBL] [Abstract][Full Text] [Related]
13. Esophageal pepsin and proton pump synthesis in barrett's esophagus and esophageal adenocarcinoma.
Samuels TL; Altman KW; Gould JC; Kindel T; Bosler M; MacKinnon A; Hagen CE; Johnston N
Laryngoscope; 2019 Dec; 129(12):2687-2695. PubMed ID: 31046139
[TBL] [Abstract][Full Text] [Related]
14. Hypermethylation of tachykinin-1 is a potential biomarker in human esophageal cancer.
Jin Z; Olaru A; Yang J; Sato F; Cheng Y; Kan T; Mori Y; Mantzur C; Paun B; Hamilton JP; Ito T; Wang S; David S; Agarwal R; Beer DG; Abraham JM; Meltzer SJ
Clin Cancer Res; 2007 Nov; 13(21):6293-300. PubMed ID: 17975140
[TBL] [Abstract][Full Text] [Related]
15. Hedgehog signaling activation in the development of squamous cell carcinoma and adenocarcinoma of esophagus.
Yang L; Wang LS; Chen XL; Gatalica Z; Qiu S; Liu Z; Stoner G; Zhang H; Weiss H; Xie J
Int J Biochem Mol Biol; 2012; 3(1):46-57. PubMed ID: 22509480
[TBL] [Abstract][Full Text] [Related]
16. Early esophageal cancer in Europe: endoscopic treatment by endoscopic submucosal dissection.
Probst A; Aust D; Märkl B; Anthuber M; Messmann H
Endoscopy; 2015 Feb; 47(2):113-21. PubMed ID: 25479563
[TBL] [Abstract][Full Text] [Related]
17. Alteration of the esophageal microbiota in Barrett's esophagus and esophageal adenocarcinoma.
Lv J; Guo L; Liu JJ; Zhao HP; Zhang J; Wang JH
World J Gastroenterol; 2019 May; 25(18):2149-2161. PubMed ID: 31143067
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in oesophageal diseases.
Al Dulaimi D
Gastroenterol Hepatol Bed Bench; 2014; 7(3):186-9. PubMed ID: 25120902
[TBL] [Abstract][Full Text] [Related]
19. Chronic Obstructive Pulmonary Disease and the Risk of Esophagitis, Barrett's Esophagus, and Esophageal Adenocarcinoma: A Primary Care Case-Control Study.
Menon S; Nightingale P; Trudgill N
J Clin Gastroenterol; 2019; 53(10):e451-e455. PubMed ID: 31008868
[TBL] [Abstract][Full Text] [Related]
20. Gastroesophageal reflux and Barrett's esophagus: a pathway to esophageal adenocarcinoma.
Schlottmann F; Molena D; Patti MG
Updates Surg; 2018 Sep; 70(3):339-342. PubMed ID: 30039277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
